抗血管生成治疗卵巢癌

Q3 Medicine Ejc Supplements Pub Date : 2020-08-01 DOI:10.1016/j.ejcsup.2020.02.003

Yolanda García García, Maria Marín Alcalá , Clara Martínez Vila

{"title":"抗血管生成治疗卵巢癌","authors":"Yolanda García García, Maria Marín Alcalá , Clara Martínez Vila","doi":"10.1016/j.ejcsup.2020.02.003","DOIUrl":null,"url":null,"abstract":"<div><p>Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 77-86"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.003","citationCount":"7","resultStr":"{\"title\":\"Anti-angiogenic therapy for ovarian cancer\",\"authors\":\"Yolanda García García, Maria Marín Alcalá , Clara Martínez Vila\",\"doi\":\"10.1016/j.ejcsup.2020.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).</p></div>\",\"PeriodicalId\":11675,\"journal\":{\"name\":\"Ejc Supplements\",\"volume\":\"15 \",\"pages\":\"Pages 77-86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.003\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ejc Supplements\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1359634920300045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634920300045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 7

摘要

血管生成是癌症的一个已知标志，在卵巢癌的发生和侵袭中起着至关重要的作用。抗血管生成药物在卵巢癌治疗中具有活性，无论是单独治疗还是与化疗、免疫治疗或聚ADP核糖聚合酶(PARP)抑制剂联合使用。我们回顾了最重要的药物的作用机制、临床活性和安全性，无论是在实际治疗中还是在卵巢癌治疗方案(新辅助、一线和复发)的当前评估中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Anti-angiogenic therapy for ovarian cancer

Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ejc Supplements 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

3.7 months

期刊介绍： EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).